Eli Reynolds
Research Subjects
Eli Reynolds has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Adam Berman
Department of Population Health, New York University Langone Health
1 shared publication- Alexander Kushnir
Leon H. Charney Division of Cardiology, Cardiac Electrophysiology, NYU Langone Health, New York University Grossman School of Medicine, New York, USA
1 shared publication - Amrita Mukhopadhyay
Leon H. Charney Division of Cardiology, Department of Medicine New York University School of Medicine New York NY
1 shared publication - Angel Marks
Duke Clinical Research Institute, Durham, NC (H.M.S., A.M., D.M.W., M.R.P., W.S.J., J.A.R.).
1 shared publication - Angela Wang
Department of Internal Medicine NYU Langone Health New York New York USA
1 shared publication - Anthony Aizer
Leon H. Charney Division of Cardiology, NYU Langone Health New York University Grossman School of Medicine New York New York USA
1 shared publication
Latest Publications
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (10)
Temporal Trends and Predictors of Access Site Crossover During PCI in Contemporary Practice: A Report From the NCDR CathPCI Registry
BACKGROUND: Randomized trials comparing radial and femoral access report access site crossover rates of 3% to 9% for radial access and 1% to 3% for femoral access. However, contemporary real-world crossover rates are not well characterized. The aim was to evaluate contemporary trends and predictors of vascular access site crossover during percutaneous coronary intervention (PCI). METHODS: We analyzed index PCI procedures recorded in the National Cardiovascular Data Registry CathPCI (Catheterization and Percutaneous Coronary Intervention) Registry from 2018 to 2024. Access site crossover was identified using documented access data, with radial-to-femoral crossover inferred when the final successful access site was femoral. Temporal trends and clinical predictors of crossover were examined. Operator experience was assessed using cumulative total and radial PCI volumes from 2011 to 2024 as captured in CathPCI Registry versions 4 and 5. RESULTS: Among 3 861 790 index PCIs, 192 902 (5.0%) involved access site crossover, with a modest increase over time. Radial-to-femoral crossover accounted for 81.2% of crossover events. Factors independently associated with crossover included older age, female sex, higher body mass index, and peripheral vascular disease. Operators with the lowest total PCI volume and the lowest radial PCI volume experienced the highest crossover rates. Notably, operators with low radial PCI volume demonstrated a substantial decline in radial-to-femoral crossover over the study period. CONCLUSIONS: In contemporary clinical practice, access site crossover rates are consistent with those reported in randomized trials. Although crossover occurs more frequently among lower-volume operators, rates decline with increasing operator experience, supporting the presence of a radial access learning curve and improvement in procedural performance over time.
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (10)
Temporal Trends and Predictors of Access Site Crossover During PCI in Contemporary Practice: A Report From the NCDR CathPCI Registry
BACKGROUND: Randomized trials comparing radial and femoral access report access site crossover rates of 3% to 9% for radial access and 1% to 3% for femoral access. However, contemporary real-world crossover rates are not well characterized. The aim was to evaluate contemporary trends and predictors of vascular access site crossover during percutaneous coronary intervention (PCI). METHODS: We analyzed index PCI procedures recorded in the National Cardiovascular Data Registry CathPCI (Catheterization and Percutaneous Coronary Intervention) Registry from 2018 to 2024. Access site crossover was identified using documented access data, with radial-to-femoral crossover inferred when the final successful access site was femoral. Temporal trends and clinical predictors of crossover were examined. Operator experience was assessed using cumulative total and radial PCI volumes from 2011 to 2024 as captured in CathPCI Registry versions 4 and 5. RESULTS: Among 3 861 790 index PCIs, 192 902 (5.0%) involved access site crossover, with a modest increase over time. Radial-to-femoral crossover accounted for 81.2% of crossover events. Factors independently associated with crossover included older age, female sex, higher body mass index, and peripheral vascular disease. Operators with the lowest total PCI volume and the lowest radial PCI volume experienced the highest crossover rates. Notably, operators with low radial PCI volume demonstrated a substantial decline in radial-to-femoral crossover over the study period. CONCLUSIONS: In contemporary clinical practice, access site crossover rates are consistent with those reported in randomized trials. Although crossover occurs more frequently among lower-volume operators, rates decline with increasing operator experience, supporting the presence of a radial access learning curve and improvement in procedural performance over time.
- 22 August 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Pulmonary Vein Isolation (PVI) Versus PVI With Posterior Wall Isolation With PFA for Paroxysmal Atrial Fibrillation
Background: The value of additional lesion sets beyond pulmonary vein isolation (PVI) for atrial fibrillation (AF) ablation is unclear. However, existing studies evaluated the utility of substrate modification with conventional energy sources. There is limited data evaluating PVI with posterior wall isolation (PWI) using pulsed field ablation (PFA). Methods: We studied consecutive cases of patients with paroxysmal AF undergoing first‐time ablation with PFA between May 6, 2024 and March 10, 2025. Procedural data collected included the number of PFA applications administered, total procedure time, and major periprocedural complications. Clinical data collected included atrial tachyarrhythmia (ATA) recurrence, stroke, and major bleeding at 1‐year follow‐up. Outcomes were compared in patients undergoing PVI alone versus PVI plus PWI. Results: A total of 249 patients were included in this study (104 PVI alone, 145 PVI plus PWI). There was no difference in ATA recurrence by Kaplan–Meier survival analysis comparing PVI alone versus PVI plus PWI (log rank test p = 0.89). When comparing PVI alone versus PVI plus PWI, there was no difference in ATA recurrence at 1 year (16% vs. 16%; p = 0.92), AF burden on continuous monitoring (2% vs. 2%; p = 0.81), total procedure time (114 vs. 107 min; p = 0.14), or major periprocedural complications (0 vs. 3; p = 0.14). Conclusion: PFA for paroxysmal AF with PVI alone or PVI plus PWI produces similar sinus rhythm maintenance without affecting procedure times or complication rates.
- 22 August 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Pulmonary Vein Isolation (PVI) Versus PVI With Posterior Wall Isolation With PFA for Paroxysmal Atrial Fibrillation
Background: The value of additional lesion sets beyond pulmonary vein isolation (PVI) for atrial fibrillation (AF) ablation is unclear. However, existing studies evaluated the utility of substrate modification with conventional energy sources. There is limited data evaluating PVI with posterior wall isolation (PWI) using pulsed field ablation (PFA). Methods: We studied consecutive cases of patients with paroxysmal AF undergoing first‐time ablation with PFA between May 6, 2024 and March 10, 2025. Procedural data collected included the number of PFA applications administered, total procedure time, and major periprocedural complications. Clinical data collected included atrial tachyarrhythmia (ATA) recurrence, stroke, and major bleeding at 1‐year follow‐up. Outcomes were compared in patients undergoing PVI alone versus PVI plus PWI. Results: A total of 249 patients were included in this study (104 PVI alone, 145 PVI plus PWI). There was no difference in ATA recurrence by Kaplan–Meier survival analysis comparing PVI alone versus PVI plus PWI (log rank test p = 0.89). When comparing PVI alone versus PVI plus PWI, there was no difference in ATA recurrence at 1 year (16% vs. 16%; p = 0.92), AF burden on continuous monitoring (2% vs. 2%; p = 0.81), total procedure time (114 vs. 107 min; p = 0.14), or major periprocedural complications (0 vs. 3; p = 0.14). Conclusion: PFA for paroxysmal AF with PVI alone or PVI plus PWI produces similar sinus rhythm maintenance without affecting procedure times or complication rates.
- Open Access
Measuring Adherence to Multiple Medications Using Guideline-Directed Medical Therapy as a Model
Background: There is no gold standard for measuring adherence to a complex medication regimen. Heart failure is a chronic disease state that requires multiple medications for optimal control, known as guideline-directed-medical therapy (GDMT), and can be used a model to explore approaches to assessing multi-medication adherence. We aimed to compare seven proportion of days covered (PDC) measures for assessing adherence to multiple GDMT medications and to evaluate their association with clinical outcomes. Methods: We conducted a large, single center, retrospective cohort study of 34,603 patients with heart failure who filled a GDMT prescription between April 2021 and July 2022. The primary outcomes were the seven PDC-based adherence measures derived from electronic health record and pharmacy data. PDC was defined as the proportion of days in which patients had possession of GDMT medications. Our secondary outcome was the combined clinical outcome of ED visits, hospitalizations, and death. Results: The seven measures provided a wide range of measured PDC adherence. Using the strictest measure, ‘each’ (>= 80% of days with each drug available) 54% of patients were considered adherent, compared with 73% measured adherence for the least restrictive measure, ‘at least one’. Variability increased with increasing number of medications across all non-average based measures. For example, using the ‘all’ measure (a more restrictive PDC measure) adherence ranged from 0.53 to 0.41 with increasing number of GDMT prescriptions. Higher PDC for each of the seven measures was associated with increased number of ED, visits, hospitalizations, and death. There was no association with the combined outcome in patients with heart failure with reduced ejection fraction. Conclusions and Relevance: There was a wide variability in adherence measures for assessing adherence to GDMT depending on the measure used. This variability has significant implications for the policy, clinical, and intervention context to which the measure is applied.
Open AccessMeasuring Adherence to Multiple Medications Using Guideline-Directed Medical Therapy as a Model
Background: There is no gold standard for measuring adherence to a complex medication regimen. Heart failure is a chronic disease state that requires multiple medications for optimal control, known as guideline-directed-medical therapy (GDMT), and can be used a model to explore approaches to assessing multi-medication adherence. We aimed to compare seven proportion of days covered (PDC) measures for assessing adherence to multiple GDMT medications and to evaluate their association with clinical outcomes. Methods: We conducted a large, single center, retrospective cohort study of 34,603 patients with heart failure who filled a GDMT prescription between April 2021 and July 2022. The primary outcomes were the seven PDC-based adherence measures derived from electronic health record and pharmacy data. PDC was defined as the proportion of days in which patients had possession of GDMT medications. Our secondary outcome was the combined clinical outcome of ED visits, hospitalizations, and death. Results: The seven measures provided a wide range of measured PDC adherence. Using the strictest measure, ‘each’ (>= 80% of days with each drug available) 54% of patients were considered adherent, compared with 73% measured adherence for the least restrictive measure, ‘at least one’. Variability increased with increasing number of medications across all non-average based measures. For example, using the ‘all’ measure (a more restrictive PDC measure) adherence ranged from 0.53 to 0.41 with increasing number of GDMT prescriptions. Higher PDC for each of the seven measures was associated with increased number of ED, visits, hospitalizations, and death. There was no association with the combined outcome in patients with heart failure with reduced ejection fraction. Conclusions and Relevance: There was a wide variability in adherence measures for assessing adherence to GDMT depending on the measure used. This variability has significant implications for the policy, clinical, and intervention context to which the measure is applied.